WASHINGTON — Shares of companies developing stem cell therapies surged Wednesday on news that the federal government has cleared 13 new stem cell lines for testing, bringing to a close nearly a decade of restrictions.
"For the first time all these programs that have been held in check by the closed stem cell policy can move forward," said Steve Brozak, president and analyst with WBB Securities, an investment brokerage focused on drug and biotech companies.
]]>